NextCure Statistics

Total Valuation

NextCure has a market cap or net worth of $36.09 million. The enterprise value is -$32.82 million.

Market Cap	36.09M
Enterprise Value	-32.82M

Important Dates

The last earnings date was Thursday, November 7, 2024, after market close.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

NextCure has 27.98 million shares outstanding. The number of shares has increased by 0.48% in one year.

Current Share Class	27.98M
Shares Outstanding	27.98M
Shares Change (YoY)	+0.48%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	1.81%
Owned by Institutions (%)	30.24%
Float	18.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.48
P/TBV Ratio	0.48
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.07, with a Debt / Equity ratio of 0.08.

Current Ratio	9.07
Quick Ratio	8.72
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -57.93% and return on invested capital (ROIC) is -35.21%.

Return on Equity (ROE)	-57.93%
Return on Assets (ROA)	-32.86%
Return on Capital (ROIC)	-35.21%
Revenue Per Employee	n/a
Profits Per Employee	-$713,634
Employee Count	82
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.56% in the last 52 weeks. The beta is 0.79, so NextCure's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	+1.56%
50-Day Moving Average	1.37
200-Day Moving Average	1.54
Relative Strength Index (RSI)	45.22
Average Volume (20 Days)	37,130

Short Selling Information

The latest short interest is 66,118, so 0.24% of the outstanding shares have been sold short.

Short Interest	66,118
Short Previous Month	73,774
Short % of Shares Out	0.24%
Short % of Float	0.37%
Short Ratio (days to cover)	1.89

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-60.54M
Pretax Income	-61.28M
Net Income	-58.52M
EBITDA	-57.53M
EBIT	-60.54M
Earnings Per Share (EPS)	-$2.09

Full Income Statement

Balance Sheet

The company has $75.31 million in cash and $6.12 million in debt, giving a net cash position of $69.19 million or $2.47 per share.

Cash & Cash Equivalents	75.31M
Total Debt	6.12M
Net Cash	69.19M
Net Cash Per Share	$2.47
Equity (Book Value)	75.59M
Book Value Per Share	2.70
Working Capital	70.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$44.51 million and capital expenditures -$521,000, giving a free cash flow of -$45.03 million.

Operating Cash Flow	-44.51M
Capital Expenditures	-521,000
Free Cash Flow	-45.03M
FCF Per Share	-$1.61

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NextCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.48%
Shareholder Yield	-0.48%
Earnings Yield	-160.90%
FCF Yield	-123.81%

Analyst Forecast

The average price target for NextCure is $4.00, which is 210.08% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.00
Price Target Difference	210.08%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-26.01%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1